Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the USA / NCT01678872
Active, not recruiting Phase 1

A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

NCT01678872 · tracked via the Priya Life Science USA tracker
Sponsor
Oxford BioMedica
Phase
Phase 1
Started
2012-08
Last updated
2026-01-14

Condition(s) studied

Age-Related Macular Degeneration

Investigational drug(s) / intervention(s)

RetinoStat

RetinoStat: Long Term Follow up of patients who received RetinoStat in a previous study

Study summary

The purpose of this study is to examine the long term safety of an experimental gene transfer agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Must have received a subretinal injection of RetinoStat * Must have been enrolled in Protocol RS1/001/10 Exclusion Criteria: * Did not receive RetinoStat® as part of the RS1/001/10 protocol

Primary outcome measure(s)

  • The incidence of adverse events — 14 years
    The number of subjects with treatment emergent adverse events.

Trial sites (3)

FacilityCityRegionStatus
University of Iowa Hospitals & Clinics Iowa City Iowa
John Hopkins University Hospital Baltimore Maryland
Oregon Health & Science University Portland Oregon

Other trials for the same condition

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration Active, not recruiting
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration Active, not recruiting
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration Recruiting
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders Active, not recruiting
ForeseeHome NRich Registry Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01678872 on ClinicalTrials.gov ↗ ← All trials in the USA